Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma
Neoadjuvant chemotherapy did not decrease the long-term survival amongst gastric adenocarcinoma survivors. Patients who received neoadjuvant chemotherapy were a selected group characterised by younger age and fewer severe comorbidities and therefore with better chances of long-term survival.
Authors
- Fredrik Mattsson (ORCID: https://orcid.org/0009-0000-1850-2760)
- Wilhelm Leijonmarck (ORCID: https://orcid.org/0000-0003-1054-512X)
- Jesper Lagergren
Institutions
- King's College London (GB)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Gastric Cancer
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1007/s10120-024-01558-7
- Citations
- 4
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Cancerfonden
- Karolinska Institutet
- Vetenskapsrådet
- Radiumhemmets Forskningsfonder